All In Biotech

Drug Trial Radar · NCT00144417

TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment

TBTC Study 28: Evaluation of a Moxifloxacin-based, Isoniazid-sparing Regimen for Tuberculosis Treatment

Last checked: Nov 19, 2026Latest source record: Aug 3, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 433 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

433

Actual

Start

Feb 2006

Primary completion

Jun 2007

Study completion Dec 2007

Sponsor

Sponsor type
Federal agency
Collaborators
Global Alliance for TB Drug Development; Bayer
First posted
Sep 5, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This double-blind, randomized controlled trial evaluates moxifloxacin versus isoniazid in daily treatment during the first two months of treatment with rifampin, pyrazinamide and ethambutol for sputum smear-positive pulmonary tuberculosis.

Conditions

  • Tuberculosis

Interventions

  • Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)Drug

    Moxifloxacin 400mg daily, 8 weeks

  • isoniazidDrug

    isoniazid, oral, 300 mg, daily, 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. • To compare the culture-conversion rate at the end of the intensive phase of therapy of the moxifloxacin regimen vs. that of the isoniazid regimenTime frame: 8 weeks

Locations

26 sites in 6 countries. Site status is shown where the registry gives one.

  • Veterans Administration Medical Center of Arkansas

    Little Rock, Arkansas

  • University of Southern California Medical Center

    Los Angeles, California

  • University of California at San Diego

    San Diego, California

  • University of California, San Francincisco

    San Francisco, California

  • Denver Public Health Department

    Denver, Colorado

  • Washington DC Veterans Administration Medical Center

    Washington D.C., District of Columbia

  • Emory University School of Medicine

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Hines Veterans Administration Medical Center

    Hines, Illinois

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland

  • Boston University Medical Center

    Boston, Massachusetts

  • New Jersey School of Medicine

    Newark, New Jersey

  • Columbia University

    New York, New York

  • Harlem Hospital, Columbia University

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Veterans Administration Tennessee Valley Health Care System

    Nashville, Tennessee

  • University of North Texas Health Science Center

    Fort Worth, Texas

  • Houston Veterans Administration Medical Center

    Houston, Texas

  • Audie L Murphy Memorial Veterans Administration Medical Center

    San Antonio, Texas

  • Seattle-King County Health Department

    Seattle, Washington

  • Hopital Universitario Clementino Fraga Filho

    Rio de Janeiro, Rio de Janeiro, Brazil

  • University of Manitoba

    Winnepeg, Manitoba, Canada

  • Montreal Chest Institute

    Montreal, Quebec, Canada

  • Nelson R. Mandela School of Medicine

    Durban, KwaZulu-Natal, South Africa

  • Agencia de Salut Publica

    Barcelona, Spain

  • Makerere University Medical School

    Kampala, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.